Oncolytic adenovirus armed with therapeutic genes
AssigneeBoard of Regents, The University of Texas System
InventorsJuan FUEYO, Candelaria GOMEZ-MANZANO, W. K. Alfred YUNG, Charles A. CONRAD, Frederick F. LANG, JR.
Life of this patent
Estimating the term…
Abstract
The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
Claims33
A method for treating a brain tumor in a patient comprising:
- a) identifying a patient having a brain tumor;
- and
- b) contacting the tumor with an oncolytic adenovirus that encodes a therapeutic gene and an E1A polypeptide that cannot bind Rb.
6-7. (canceled)
10-11. (canceled)
(canceled)
A method of treating cancer in a patient comprising:
- a) administering to a patient an effective amount of a composition comprising an oncolytic adenovirus comprising (i) a nucleic acid, wherein the nucleotides encoding amino acids 122-129 of the encoded E1A polypeptide are deleted, and (ii) an expression cassette comprising a polynucleotide encoding a yeast cytosine deaminase;
- and
- b) administering an effective amount of a pro-drug, wherein the pro-drug is metabolized to a cytotoxic drug by a polypeptide encoded by the yeast cytosine deaminase.
20-21. (canceled)
(canceled)
(canceled)
31-33. (canceled)
(canceled)
38-39. (canceled)
Dependencies are inferred from the claim text.